Adjuvant chemotherapy may have no significant survival benefit in older patients with stage II/III gastric cancer: a multicenter retrospective study

• DOI: 10.1007/s00432-025-06230-w
• Publication Date: 2025-05-26T21:52:50Z
• Authors: Zheng-Zheng Shen; En-Ze Li; Ruo-Lan Zhang; Meng-Xuan Cao; Yan-Qiang Zhang; Qing Yang; Can Hu; Si-Wei Pan; Zhi-Yuan Xu; Zai-Sheng Ye; Jing-Yang He
• Keywords: Hematology; Adjuvant Chemotherapy

Postoperative adjuvant chemotherapy is known to enhance cure rates and thus recommended for stages pII pIII. However, specific guidelines such treatment in elderly gastric cancer (GC) patients are currently lacking. This study examines the impact of on postoperative survival these patients. We reviewed a total 7749 with GC who underwent radical gastrectomy at Zhejiang Cancer Hospital Fujian from January 2007 December 2019. conducted univariate multivariate Cox regression analyses investigate clinicopathological factors overall (OS) cancer-specific (CSS) Additionally, we created meta-analysis forest plot employed propensity score matching (PSM) mitigate confounding bias. Age were independent risk OS CSS. Stratified analysis based use revealed statistically significant difference CSS between younger did not receive chemotherapy. In contrast, no differences observed older or without These findings remained consistent after (PSM). stage II/III GC; aged ≥ 75 years, shared decision-making should be made taking into account functional status comorbidities, rather than conventional